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intestinal inorganic phosphate (Pi) transport.1 PFA com-
petitively inhibits type II Na/Pi cotransporters (intestinal
NaPi-IIb, and renal NaPi-IIa and NaPi-IIc).1 Conversely, it is
not an inhibitor of type III Pi transporters, namely the
ubiquitous Pit-1 and Pit-2, as we have shown2 and as Professor
Giachelli has demonstrated recently in this journal.3
PFA successfully prevents Pi-induced calcification of
vascular smooth muscle cells (VSMCs; EC50 of 60 mM),
4,
but it inhibits Pi transport with very low affinity (Ki 2.6 mM)
2
because these cells only express type III Na/Pi cotranspor-
ters.2 Therefore, the mechanism of vascular prevention by
PFA should be different from that of Pi-transport inhibition,
as we have described recently (Figure 1).
In a recent study,4 we clarified the mechanism whereby
PFA prevents VSMC calcification. We showed that PFA
inhibits calcium-phosphate deposition in a process that is
independent of any cell activity or metabolism and that is
similar to the physicochemical mechanism of bisphosphonate
drugs and pyrophosphate.4 This rationale was already
proposed decades ago by several researchers, and it also
coincides with a recent study by Prof. O’Neill’s group.5
Therefore, the use of PFA as a tool to inhibit Pi transport in
vascular calcification research should be avoided, because the
concentrations of PFA that significantly inhibit Pi transport
in VSMC also exhibit cytotoxic side effects.4
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Despite the fact that phosphonoformic acid (PFA) is a very
weak inhibitor of the type III phosphate transporters
present in vascular smooth muscle, its inhibition of
calcification in cultured vascular smooth muscle cells
(VSMCs) has been used to support a role for phosphate
transport in vascular calcification.1 However, as pointed
out by Villa-Bellosta and Sorribas,2 PFA is also a non-
hydrolyzable analog of pyrophosphate (PPi). PPi is a
potent, direct inhibitor of hydroxyapatite crystal forma-
tion that inhibits vascular calcification in vitro and in vivo,
a property shared by a number of analogs, including
bisphosphonates.3 Not surprisingly, Villa-Bellosta and
Sorribas have shown that this is also the mechanism by
which PFA inhibits calcification in VSMCs. This is yet
another example of a ‘specific’ inhibitor that, like most
‘specific’ inhibitors, is not specific.
Subsequent studies using antisense RNA directed
against Pit-1 have also shown inhibition of calcification
in VSMCs,4 supporting a role for phosphate transport.
However, caution must also be exercised in interpreting
these results because VSMCs undergo substantial pheno-
typic changes in culture and lack the normal elastin
matrix, which is the site of medial calcification in vivo.
Using the whole aorta culture method, we have been
unable to duplicate many of the findings in VSMCs related
to medial calcification. Thus, the intriguing and potentially
important role of phosphate transporters in vascular
calcification, although widely cited, remains to be proven
in a relevant model.
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Figure 1 | Effect of phosphonoformic acid (PFA) on inorganic
phosphate (Pi) transport and calcium deposition in vascular
smooth muscle cells.
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